SCHEMBL1733469

SCHEMBL1733469

NC(=O)c1cc(-c2ccccc2OC(F)(F)F)nc(N2CCCCC2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
HPGD P15428 4/20 0.61
KDM4E B2RXH2 4/20 0.61
GAA P10253 2/20 0.61
HSD17B10 Q99714 2/20 0.61
TSHR P16473 1/20 0.61
CASP1 P29466 1/20 0.61
CASP7 P55210 1/20 0.61
TP53 P04637 1/20 0.53
MAPT P10636 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HTT P42858 2/20 0.48
GLA P06280 1/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
SCN9A Q15858 12/20 0.46
CYP2C9 P11712 2/20 0.46
S1PR1 P21453 2/20 0.45
SCN10A Q9Y5Y9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734273 0.86 ALDH1A1 (0.65) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1733535 0.84 ALDH1A1 (0.66) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1733460 0.84 KDM4E (0.65) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1735696 0.83 KDM4E (0.61) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1733464 0.82 KDM4E (0.70) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1734370 0.81 KDM4E (0.74) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1734159 0.80 KDM4E (0.67) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1733689 0.80 ALDH1A1 (0.61) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1734174 0.80 ALDH1A1 (0.70) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1734590 0.78 KDM4E (0.63) ALDH1A1HPGDKDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 ALDH1A1 2670/4885HPGD 1462/4885KDM4E 3910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.